China's pharmaceutical insurance reform has made life-saving drugs more accessible, including cancer treatments, by significantly reducing prices.
The country is expanding its biotech industry, conducting more clinical trials than the U.S. and licensing discoveries to American companies.
China's drug reimbursement system is transitioning to support innovation, exploring diversified payment mechanisms for innovative drugs.